
|Videos|March 8, 2021
Practice Pearl 2: Review of Studies for Prevention of VTE
Paul Ament, PharmD, reviews the data from studies looking into the prevention of VTEs and Riley Bowers, PharmD, shares the real-world data to the studies.
Advertisement
Episodes in this series

Advertisement
Related to this article

Pharmacists can help patients start buprenorphine for opioid use disorder by confirming when to take the first dose, whether another opioid continues during initiation, and who will manage symptoms and follow-up.

In older veterans, mRNA-1283 was associated with lower risks of medically attended COVID-19 and hospitalization than BNT162b2.

Pharmacists can use medication therapy management to screen for diabetes, educate patients about medication adherence and lifestyle modifications, and support early action.

In a phase 3 trial of children aged 6 to younger than 12 years, once-weekly semaglutide reduced BMI 16.2 percentage points more than placebo at 68 weeks.

An analysis of 40 economic studies found PCV20 and PCV21 outperformed older strategies, while low uptake and racial gaps limited the benefit of vaccination.

Higher doses of injectable semaglutide have been shown to cause greater weight loss than standard doses with a similar safety profile.

Age-related changes in drug clearance, polypharmacy, and chronic conditions make product selection in the cough and cold aisle a key counseling opportunity for pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Survodutide for Obesity and CV Risk: Liver, Lipids, and Beyond
2
mRNA-1283 Associated With Lower Risk of Medically Attended COVID-19 Than BNT162b2 in Older Veterans
3
Cemdisiran Approved as First siRNA Therapy for Myasthenia Gravis
4
Long-Acting HIV Injectables in Viremia and New Tenofovir-Free Oral Options
5













